NO133838B - - Google Patents
Download PDFInfo
- Publication number
- NO133838B NO133838B NO901/71A NO90171A NO133838B NO 133838 B NO133838 B NO 133838B NO 901/71 A NO901/71 A NO 901/71A NO 90171 A NO90171 A NO 90171A NO 133838 B NO133838 B NO 133838B
- Authority
- NO
- Norway
- Prior art keywords
- magnesium
- acid
- skin
- hair
- compounds
- Prior art date
Links
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 12
- 229910052749 magnesium Inorganic materials 0.000 claims description 12
- 239000011777 magnesium Substances 0.000 claims description 12
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 150000001413 amino acids Chemical class 0.000 claims description 5
- 210000004209 hair Anatomy 0.000 claims description 5
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 235000015110 jellies Nutrition 0.000 claims description 3
- 239000003921 oil Substances 0.000 claims description 3
- 239000003883 ointment base Substances 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 2
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 2
- 235000020778 linoleic acid Nutrition 0.000 claims description 2
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 2
- 229960004488 linolenic acid Drugs 0.000 claims description 2
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 2
- 229940055726 pantothenic acid Drugs 0.000 claims description 2
- 235000019161 pantothenic acid Nutrition 0.000 claims description 2
- 239000011713 pantothenic acid Substances 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 7
- 239000013522 chelant Substances 0.000 description 5
- 150000002681 magnesium compounds Chemical class 0.000 description 4
- 159000000003 magnesium salts Chemical class 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000004475 Arginine Substances 0.000 description 3
- -1 MgCl2 Chemical class 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- JOOXCMJARBKPKM-UHFFFAOYSA-N 4-oxopentanoic acid Chemical compound CC(=O)CCC(O)=O JOOXCMJARBKPKM-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229910001425 magnesium ion Inorganic materials 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 description 2
- OHXPGWPVLFPUSM-KLRNGDHRSA-N 3,7,12-trioxo-5beta-cholanic acid Chemical compound C1CC(=O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)C(=O)C[C@@H]3[C@]21C OHXPGWPVLFPUSM-KLRNGDHRSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002997 dehydrocholic acid Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000002768 hair cell Anatomy 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000008311 hydrophilic ointment Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 229940040102 levulinic acid Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Analogifremgangsmåte for fremstilling av nye terapeutisk aktive heterocykliske forbindelser.Analogous process for the preparation of new therapeutically active heterocyclic compounds.
Description
Hud-, hår- og neglepleiemiddel. Skin, hair and nail care product.
Det er kjent at magnesiumionet har visse fysiologiske virkninger, f. eks. utvi-dende virkning på det perifere karsystem og sedativ virkning på det vegetative nerve-system, av hvilken grunn magnesiumionet i form av vannoppløselige salter, som MgCl2, MgS04, MgSjjO.., eller også som magnesiumsalter av organiske syrer, f. eks. nikotin-syre, levulinsyre eller dehydrokolsyre er blitt innført blant legemidlene. It is known that the magnesium ion has certain physiological effects, e.g. expanding effect on the peripheral vascular system and sedative effect on the vegetative nervous system, for which reason the magnesium ion in the form of water-soluble salts, such as MgCl2, MgS04, MgSjjO.., or also as magnesium salts of organic acids, e.g. nicotinic acid, levulinic acid or dehydrocholic acid have been introduced among the drugs.
Det er nå blitt funnet at magnesiumet også ved ytre anvendelse i kosmetiske midler, f. eks. i salver, emulsjoner, oljer, geléer eller vann, utøver en gunstig virkning på det epiteliale vev, hud, hår og negler, som gir utslag på pleiende og vekst-fremmende måte og beror på en aktivering av de tropotrope fermenter i hudcellene. For dette formål anvendes magnesiumet ifølge oppfinnelsen som forbindelse, nem- I lig som chelat, eller som salt med en amo-nosyre som glykolol, p-aminobenzoesyre, asparginsyre, cystein, som salt av linol- og linolensyren, eller pantotensyren. It has now been found that magnesium is also used externally in cosmetic products, e.g. in ointments, emulsions, oils, jellies or water, exerts a beneficial effect on the epithelial tissue, skin, hair and nails, which results in a nurturing and growth-promoting way and depends on an activation of the tropotropic ferments in the skin cells. For this purpose, the magnesium according to the invention is used as a compound, namely as a chelate, or as a salt with an amino acid such as glycolol, p-aminobenzoic acid, aspartic acid, cysteine, as a salt of linoleic and linolenic acid, or pantothenic acid.
Magnesiumforbindelsene av disse forskjellige anioniske komponenter anvendes enkeltvis eller i kombinasjon. Til gruppen av anvendelige aminosyrekomponenter hø-rer også slike, som på grunn av sin basiske egenskap med magnesiumet danner orga-nokjemiske kompleksforbindelser av che-latkarakter. Disse magnesiumforbindelser anvendes i i og for seg kjente salvegrunnlag, emulsjoner, oljer, geléer eller vann eller alkoholiske oppløsninger i oppløst, emulgert eller dispergert form. The magnesium compounds of these different anionic components are used individually or in combination. The group of applicable amino acid components also includes those which, due to their basic properties, form organochemical complex compounds of a chelate nature with magnesium. These magnesium compounds are used in per se known ointment bases, emulsions, oils, jellies or water or alcoholic solutions in dissolved, emulsified or dispersed form.
Ved dette har magnesiumforbindelsene av aminosyrene vist seg særlig for-delaktige, da de i blodet og kroppsvæskene bare undergår liten dissosiasjon og syre-resten får fungere samtidig som medbrin-ger for spesifikk innførsel av magnesiumet i hud- og hårcellene. På denne måte opp-nås intracellulært en optimal resorpsjon av det anvendte magnesium i hud- og hår-vekstens moderceller, som utmerker seg ved sterk tropotrop stoffutvekslingsakti-vitet. In this way, the magnesium compounds of the amino acids have proven to be particularly advantageous, as they only undergo slight dissociation in the blood and body fluids and the acid residue can function at the same time as bringing about the specific introduction of the magnesium into the skin and hair cells. In this way, an optimal resorption of the used magnesium is achieved intracellularly in the mother cells of skin and hair growth, which are characterized by strong tropotropic metabolic activity.
På grunn av deres gode oppløselighet i salvegrunnlag såvel som i alkoholiske vann er den ytre anvendelse av de nevnte magnesiumforbindelser fordelaktig i en-hver henseende. For oppnåelse av den nødvendige dybder esorps jon tjener for-trinnsvis vannoppløselige fettstoffer som salvegrunnlag med høyt innhold av partial-glycerider og hydroxylgruppeholdige fett-syrekjeder, som de som f. eks. er i han-delen under varenavnene «Imhausen S mod» eller «Imhausen 378». Due to their good solubility in ointment bases as well as in alcoholic waters, the external application of the mentioned magnesium compounds is advantageous in every respect. In order to achieve the required depth of absorption, water-soluble fatty substances with a high content of partial glycerides and hydroxyl group-containing fatty acid chains, such as those that e.g. is in the male section under the product names "Imhausen S mod" or "Imhausen 378".
For fullstendighets skyld skal det her vises til at f. eks. amerikansk patent nr. 2.719.811 omtaler forskjellige komplekse forbindelser av en rekke metaller, blant disse også magnesium, med oxysyrer, som sitron- og vinsyre og andre. Disse syrer er på grunn av sin styrke og den høye dissosiasjon for saltene ikke egnet som negative rester med magnesium for resorptiv anvendelse i kosmetiske midler. For the sake of completeness, it should be noted here that e.g. US patent no. 2,719,811 mentions various complex compounds of a number of metals, among these also magnesium, with oxyacids, such as citric and tartaric acids and others. Due to their strength and the high dissociation for the salts, these acids are not suitable as negative residues with magnesium for resorptive use in cosmetic agents.
I de tyske patenter nr. 601.474, 626.147, 633.661 og 642.344 nevnes for tilblanding til hudpuddere eller kremer magnesiumsalter av stearin-, undekan-, heptyl-, nonyl-, og tridecylsyre og disses mercapto- eller al-koxyderivater. Disse stoffer har pigment-karakter og resorberes ikke av huden. I motsetning hertil trenger magnesiumsal-tene ifølge oppfinnelsen inn i det indre av cellene i hudvevet og utøver sin virkning der. In the German patents no. 601,474, 626,147, 633,661 and 642,344, magnesium salts of stearic, undecane, heptyl, nonyl and tridecyl acid and their mercapto or alkoxy derivatives are mentioned for admixture to skin powders or creams. These substances have a pigment character and are not absorbed by the skin. In contrast, the magnesium salts according to the invention penetrate into the interior of the cells in the skin tissue and exert their effect there.
I det tyske patent nr. 891.323 beskrives metallproteiner, blant annet også magne-siumproteinat i kosmetiske produkter i form av kremer eller emulsjoner. I motsetning til metallproteinatene har magnesium-saltene etter nærværende oppfinnelse den fordel at de resorberes vesentlig lettere og således sikrere trenger inn i cellenes indre. German patent no. 891,323 describes metal proteins, including magnesium proteinate in cosmetic products in the form of creams or emulsions. In contrast to the metal proteinates, the magnesium salts according to the present invention have the advantage that they are resorbed significantly more easily and thus more reliably penetrate into the interior of the cells.
Eksempel 1. Example 1.
Man anvender til fremstilling av en hårvekstfremmende hydrofil salve: The following are used to produce a hair growth-promoting hydrophilic ointment:
Eksempel 2. Example 2.
For fremstilling av et hårvann anvendes: For the production of a hair lotion, use:
Eksempel 3. Example 3.
For fremstilling av hudsalve anvendes: For the production of skin ointment, use:
For fremstilling av magnesiumargininche-lat suspenderes 1 mol av magnesiumcarbo-nat og 1 mol arginin i 1000 cm<3> vann og oppvarmes svakt, hvorved aminosyren går i oppløsning i løpet av chalatdannelsen. Etter noen henstand av oppløsningen ut-skilles magnesiumargininchelatet som fjer-nes fra oppløsningsmidlet og tørres skarpt. For the production of magnesium arginine chelate, 1 mol of magnesium carbonate and 1 mol of arginine are suspended in 1000 cm<3> of water and heated slightly, whereby the amino acid dissolves during the chelate formation. After some standing of the solution, the magnesium arginine chelate separates out, which is removed from the solvent and dried sharply.
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH359870A CH533639A (en) | 1970-03-11 | 1970-03-11 | Benzo cyclo hepta-thiophenes |
| CH1159370A CH531000A (en) | 1970-03-11 | 1970-07-31 | Process for the preparation of new benzocycloheptathiophenes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO133838B true NO133838B (en) | 1976-03-29 |
| NO133838C NO133838C (en) | 1976-07-07 |
Family
ID=25693399
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO90171A NO133838C (en) | 1970-03-11 | 1971-03-10 |
Country Status (16)
| Country | Link |
|---|---|
| JP (1) | JPS5217030B1 (en) |
| BG (1) | BG22398A3 (en) |
| CS (1) | CS185562B2 (en) |
| DD (1) | DD100000A5 (en) |
| DK (1) | DK134404B (en) |
| ES (2) | ES389044A1 (en) |
| FI (1) | FI52980C (en) |
| HU (1) | HU162868B (en) |
| IE (2) | IE34997B1 (en) |
| IL (1) | IL36370A (en) |
| IT (1) | IT7827770A0 (en) |
| MY (1) | MY8300201A (en) |
| NO (1) | NO133838C (en) |
| PL (1) | PL84083B1 (en) |
| SU (1) | SU512711A3 (en) |
| YU (2) | YU35019B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI429641B (en) | 2008-01-30 | 2014-03-11 | Nippon Zoki Pharmaceutical Co | Piperidine derivative |
-
1971
- 1971-03-05 SU SU1628614A patent/SU512711A3/en active
- 1971-03-09 IL IL36370A patent/IL36370A/en unknown
- 1971-03-09 YU YU58671A patent/YU35019B/en unknown
- 1971-03-09 ES ES389044A patent/ES389044A1/en not_active Expired
- 1971-03-09 CS CS171771A patent/CS185562B2/en unknown
- 1971-03-09 PL PL14675171A patent/PL84083B1/pl unknown
- 1971-03-09 HU HUSA002175 patent/HU162868B/hu unknown
- 1971-03-09 FI FI68371A patent/FI52980C/fi active
- 1971-03-10 BG BG1700471A patent/BG22398A3/xx unknown
- 1971-03-10 NO NO90171A patent/NO133838C/no unknown
- 1971-03-10 DK DK111471A patent/DK134404B/en not_active IP Right Cessation
- 1971-03-10 DD DD16465971A patent/DD100000A5/xx unknown
- 1971-03-10 IE IE29971A patent/IE34997B1/en unknown
- 1971-03-10 JP JP1302171A patent/JPS5217030B1/ja active Pending
-
1973
- 1973-06-30 ES ES416480A patent/ES416480A1/en not_active Expired
-
1974
- 1974-07-15 IE IE149474A patent/IE34998B1/en unknown
-
1978
- 1978-03-24 YU YU69978A patent/YU35254B/en unknown
- 1978-09-15 IT IT7827770A patent/IT7827770A0/en unknown
-
1983
- 1983-12-30 MY MY8300201A patent/MY8300201A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5217030B1 (en) | 1977-05-12 |
| IE34997B1 (en) | 1975-10-15 |
| IE34998L (en) | 1975-10-15 |
| BG22398A3 (en) | 1977-02-20 |
| FI52980C (en) | 1978-01-10 |
| CS185562B2 (en) | 1978-10-31 |
| YU35254B (en) | 1980-10-31 |
| IL36370A (en) | 1974-10-22 |
| SU512711A3 (en) | 1976-04-30 |
| IT7827770A0 (en) | 1978-09-15 |
| DK134404C (en) | 1977-04-04 |
| ES416480A1 (en) | 1976-10-16 |
| HU162868B (en) | 1973-04-28 |
| IE34997L (en) | 1971-09-11 |
| IL36370A0 (en) | 1971-05-26 |
| NO133838C (en) | 1976-07-07 |
| ES389044A1 (en) | 1974-02-01 |
| YU69978A (en) | 1980-04-30 |
| DK134404B (en) | 1976-11-01 |
| IE34998B1 (en) | 1975-10-15 |
| PL84083B1 (en) | 1976-02-28 |
| FI52980B (en) | 1977-09-30 |
| YU58671A (en) | 1979-12-31 |
| YU35019B (en) | 1980-06-30 |
| DD100000A5 (en) | 1973-09-05 |
| MY8300201A (en) | 1983-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU6454690A (en) | Process for preparing an effervescent aqueous solution having an emollient action on the cuticle of the nails, composition for carrying out the said process and corresponding cosmetic treatment | |
| CN107674129B (en) | Schizophyllan phosphorylated derivative and preparation method and application thereof | |
| ES2075011T3 (en) | USE OF GAMMA-HYDROXYBUTRIC ACID SALTS TO PREPARE PHARMACEUTICAL COMPOSITIONS FOR USE IN THE TREATMENT OF ALCOHOLISM, AND THE COMPOSITIONS OBTAINED. | |
| DE1099128B (en) | Preparations for the care and promotion of the growth of the skin, hair and nails | |
| MX2009012742A (en) | Novel active ingredient in cicatrization and use thereof. | |
| MX2014015799A (en) | Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof. | |
| WO2016079912A1 (en) | Hair papilla cell activator | |
| EP2524686A1 (en) | Pigmentation-preventing or -ameliorating agent | |
| NO133838B (en) | ||
| NO20011091L (en) | Unsaturated hydroxymic acid derivatives as PARP inhibitors | |
| CH609863A5 (en) | Cosmetic treatment process and products enabling it to be carried out | |
| CN102985093A (en) | Agent for suppressing the formation of abnormal skin cells caused by exposure to light | |
| MX169354B (en) | PROCEDURE FOR THE TREATMENT OF SKIN | |
| ES2074257T3 (en) | AMINO ACID DERIVATIVES. | |
| DE10393402T5 (en) | Agent and toiletry or pharmaceutical composition for accelerating uptake of basic amino acids into cells | |
| RU2642277C2 (en) | Method for conserving and stabilizing proteins | |
| US2303765A (en) | Preparation of ammonium allantoinate | |
| WO2005016297A1 (en) | Hair regenerator | |
| Mishchenko et al. | Study of the echinochrome stabilityand the products of its oxidative transformation | |
| GB604350A (en) | Process for reducing the viscosity of or for liquefying mucus and preparations for use therein | |
| DE102010015120A1 (en) | Hair growth and depilatory and its use | |
| TR202021285A1 (en) | FORMULATION CONTAINING ERBIUM BORATE FOR THE PREVENTION AND TREATMENT OF WOUND SCAR | |
| JPS54100318A (en) | Aliphatic acid and aspartic acid ester of glycerine, its preparation, and amphoteric surfactant containing it as active component | |
| RU2021134935A (en) | METHOD FOR CORNEAL BURN TREATMENT | |
| BOREL et al. | Influence of Some Purified Plasma Proteins on Collagen Synthesis in vitro |